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Abstract
Fracture healing is characterized by inflammation, cartilage formation, bone deposition,
and remodeling. Endochondral ossification is an important part of callus formation that relies on
the maturation of chondrocytes. Early in their maturation these cells express collagen type II
alpha 1 chain (COL2A1) and express collagen type X alpha 1 chain (COL10A1) as they mature
further and become hypertrophic chondrocytes. Activation of the insulin pathway is considered a
primary factor involved in the initiation of chondrogenesis and its progression during bone
healing. Insulin mimetics like zinc chloride (ZnCl2) have been shown to improve bone healing
outcomes and enhance bone healing, but the mechanism by which insulin mimetics enhance
bone healing is unclear. We hypothesized that treatment of chondrocytes with ZnCl2 would
activate AKT within the insulin-signaling pathway and promote chondrocyte maturation and
differentiation similar to insulin. The ATDC5 chondrogenic cell line was treated zinc chloride
(ZnCl2) and evaluated for chondrogenesis by measuring calcium deposition, proteoglycan
synthesis, protein expression, and gene expression at specific timepoints between 0-28 days. Our
data demonstrates that ZnCl2 induces the insulin pathway by phosphorylation of Akt. ZnCl2
treatment promotes chondrogenesis as seen by increased expression of chondrogenic markers
COL2A1 and COL10A1 and calcium deposition.

Keywords: chondrocyte, maturation, zinc, insulin, diabetes, fracture, regeneration, ossification
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Introduction
Diabetes and Bone Healing
Diabetes mellitus is a metabolic disorder which is known to have improperly regulated
insulin levels. Many complications associated with diabetes exist including decreased bone
mineral density and impaired bone healing [6]. The bone impairment is projected to rise from
171 million patients in 2000 to 366 million in 2030 [26]. Research has shown that insulin given
locally at fracture sites accelerates fracture healing in both diabetics and non-diabetics. Insulin
has been shown to be essential to the upregulation of chondrogenesis. Insulin insufficiency,
hyperglycemia and oxidative stress are hallmarks of both Type 1 diabetes (T1DM) and Type 2
diabetes (T2DM). These diabetic conditions reduce osteoblast differentiation, increase osteoclast
activity, and alter apoptosis of chondrocytes and osteoblasts leading to impaired fracture healing
in diabetic patients [14-21]. Clinical studies also show that diabetes delays fracture healing. In
diabetic patients, fracture union time (normal fracture healing) may be prolonged by 87%.
Diabetes is also associated with a relative risk of 3.4-fold for complications in osseous healing,
including delayed reunion (prolonged fracture healing), non-union, redislocation or
pseudoarthrosis [10]. Diabetics have slower healing rates and have higher risk of re-injury than
non-diabetics. Local insulin treatment applied at the fracture site in both diabetics and nondiabetics, demonstrated accelerated fracture healing [10]. Topping et al [32] reported a 54-70%
decrease in Type X collagen in the fracture callus of diabetic rates and suggested that this might
have a role in defective diabetic fracture healing. These studies support the theory that diabetes
might affect fracture healing at the stage of cartilage formation [10, 32].
Bone regeneration is a complex, well-orchestrated physiological process of bone
formation, which can be seen during normal fracture healing, and is involved in continuous

6
remodeling throughout adult life [1]. Fracture healing is a common form of bone regeneration
and is characterized by inflammation, cartilage formation, cartilage bridging, bone deposition,
and remodeling. The ability of fractures to regenerate and undergo repair may be compromised
when an insufficient osteogenic reaction is observed in the fracture callus, and can result in
atrophic nonunion [30]. An atrophic nonunion occurs when no callus is formed often due to
impaired bone healing caused by vascular (e.g. impaired blood supply) or metabolic
complications (e.g. diabetes). These atrophic nonunions are solved with bone healing
augmentation instead of a mechanical approach which would employ the use of nails, pins, or
other hardware. Immediately following a fracture, a hematoma forms at the site of injury
(primary fracture healing) acting as a protective blood clot to mediate the inflammatory process
and contribute to the removal and replacement of necrotic bone with a new bone matrix
(secondary fracture healing) [4]. The hematoma contains fracture debris and initiates a proinflammatory cascade by recruiting immune cells from the surrounding soft tissues, lymphatic
system, and vasculature. Within a hematoma a low pH microenvironment is formed where
inflammatory cells secrete pro-inflammatory cytokines [tumor necrosis factor α (TNF-α),
interleukin-1β (IL-1β), and IL-6] to activate the polymorphonuclear neutrophils and M1 (or proinflammatory) macrophages that are recruited to manage this acute inflammation stage [40].
Traumatic inflammation during fracture healing is a key sign that inflammatory cells and bone
cells are interacting with each other through common cytokines, receptors, transcription factors,
and signaling molecules due to communication between cells of the monocyte-macrophageosteoclast and MSC-osteoblast lineages [8]. Fracture healing benefits from an inflammatory
response triggered by the immune system to stimulate secretion of signaling molecules that
contribute to the healing process. For example, matrix metalloproteinases (MMPs) are a family
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of zinc-dependent endopeptidases that play a crucial role in various physiological processes
including tissue remodeling and organ development, in the regulation of inflammatory processes,
and in diseases such as cancer [92]. Inflammatory cells immediately collaborate with the
complement system, coagulation cascade, and neutrophils along with “emergency signals”
triggered by cytokine/chemokine network post-trauma as the “first line of defense” initiated by
innate immunity.
Indirect (secondary) fracture healing has other key events that proceed hematoma
formation, such as acute inflammation (neutrophils and macrophages are recruited, and proinflammatory cytokines are produced), granulation tissue formation (angiogenesis), callus
formation (MSCs differentiated into chondrocytes) and remodeling (formation of chondroblasts
and osteoclasts) [5]. Inflammatory cytokines are known to have negative effects on bone, joints,
and implanted material when prolonged or chronic expression occur [34]. Tissue regeneration
requires a brief yet highly critical regulated secretion of inflammatory cytokines immediately
following an acute injury. Acute inflammatory response peaks within the first 24 hours and is
complete after 7 days [35]. Secretion of inflammatory cytokines such as tumor necrosis factor
alpha (TNF-α), MMPs, interleukin-1 (IL-1), IL-6, IL-11, and IL-18 are known to promote
angiogenesis and recruit other proinflammatory cytokines initially an acute injury (Figure 1).
MMPs participate in regulating mechanisms in all of repair processes. MMPs can activate
cytokines and chemokines by cleaving them from the cell surface or processing them to increase
their activity, or degrade them, thereby inhibiting inflammatory signals. MMPs are involved in
remodeling the ECM either directly by proteolytic degradation of proteins, such as collagens, or
indirectly via their ability to affect cell behavior. Alteration of the ECM is integral to the
resolution of wound healing but also has implication in regulation of inflammation [92].
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Figure 1: An overview of cytokine-mediated regulation of synovial interactions. Source McInnes & Schett (2007).

The TNF-α concentration has been shown to peak at 24 hours and return to baseline
within 72 hours post trauma [18]. Within that timeframe, TNF-α is expressed by macrophages,
and act as a chemotactic agent to recruit necessary cells such as neutrophils, chondrocytes, and
osteoblasts [36]. In vitro studies have shown that TNF-α induces osteogenic differentiation of
MSCs [36-38]. Osteogenic differentiation is mediated by TNFR1 and TNFR2 receptors
expressed on both osteoblasts and osteoclasts. Interleukins, IL-1 and IL-6, are expressed during
osteogenic differentiation and is believed to be most important for fracture healing [35-38]. IL-1
is produced by macrophages in the acute phase of inflammation and induces production of IL-6
in osteoblasts, promotes the production of the primary cartilaginous callus, and promotes
angiogenesis at the injured site by activating either of its two receptors, IL-1RI or IL-1RII [3638]. IL-6 is only produced during the acute phase and stimulates angiogenesis, vascular
endothelial growth factor (VEGF) production, and the differentiation of osteoblasts and
osteoclasts [39]. The anti-inflammatory state is due largely to the phenotypic modulation
(transition from M1) of macrophages to the M2 (or alternatively activated, anti-inflammatory
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macrophages) population in the fracture callus. These anti-inflammatory M2 macrophages
secrete a battery of cytokines and growth factors to promote tissue repair and angiogenesis, such
as, IL-10, PDGF, VEGF, transforming growth factor-β (TGFβ), epidermal growth factor (EGF),
and arginase [40].
Figure 2: Femur fracture repair. Source Einhorn, T. A., & Gerstenfield, L.C. (2014).

Angiogenesis is the formation of new blood vessels which is controlled by chemical
signals that can stimulate both repair of damaged blood vessels and formation of new blood
vessels [42]. Angiogenesis involves migration, growth, and differentiation of vascular
endothelial cells aligned inside the wall of blood vessels [42]. Local and systemic factors such as
fibroblast growth factor (FGF), transforming growth factor (TGF), bone morphogenetic protein
(BMP) and vascular endothelial growth factor (VEGF), are active during fracture healing (Figure
2) and are known to have direct or indirect chondrogenic, osteogenic and/or angiogenic
functions. Endogenous VEGF is a key player in bone repair, where its temporal and spatial
expression pattern corresponds to the one observed during long bone development [42, 43].
VEGF is a critical growth factor for normal angiogenesis and appropriate callus architecture and
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is induced in osteoblasts. It regulates recruitment, survival and activity of osteoclasts, endothelial
cells, and osteoblasts [43]. Also, VEGF has been observed to play a major role in cartilage
maturation and resorption. Produced by hypertrophic chondrocytes, VEGF initiates the
endochondral ossification cascade by recruiting and/or differentiating osteoclastic cells that
resorb cartilage and by attracting osteoblasts [44, 45]. Inhibition of VEGF activity disrupts
angiogenesis and results in non-unions (i.e. a failure to establish a bony bridging of the fracture
gap) and delayed unions (i.e. a failure to establish a bony bridging of the fracture gap within a
clinically reasonable period of time approximately 3-12 weeks for common fractures) [43].
Therefore, uninhibited growth factor activity is required to promote angiogenesis and appropriate
bone bridging formation during fracture healing.
Bone Formation
There are two major modes of bone formation that involve the transformation of a
preexisting mesenchymal tissue into bone tissue: intramembranous ossification and
endochondral ossification [2]. Intramembranous ossification is the process of direct bone
formation, where osteochondral progenitors differentiate directly into osteoblasts [40].
Intramembranous ossification also occurs in the bones of the skull where neural crest-derived
mesenchymal cells proliferate and condense into compact nodules [2]. Osteoblasts synthesize an
ECM containing Type I collagen. During intramembranous healing, bone spicules created from
the osteoblasts fuse to form a trabeculated bone that is eventually fully remodeled into a cortical
bone ultrastructure through the coordinated action of osteoblasts and osteoclasts [40].
Endochondral ossification is an indirect bone formation process and an important mechanism for
callus formation that relies on the differentiation of mesenchymal stem cells (MSCs). Cartilage is
produced via maturation of chondrocytes and is later replaced by bone.
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All bones from the base of the skull down, except for the clavicles, are formed this way.
The process of endochondral ossification can be divided into five stages. First, MSCs committed
to endochondral ossification differentiate into chondroblasts. Chondroblasts secrete cartilage
ECM, resulting in a cartilage model of the bone. Second, committed MSCs condense into
compact nodules and differentiate into chondrocytes that proliferate rapidly to form the model
for the bone (cartilage-specific extracellular matrix (ECM). The cartilage model continues to
grow as chondrocytes divide and more ECM is secreted, a processc called interstitial growth.
Appositional growth ensues when new chondroblasts in the perichondrium secrete matrix on the
periphery of the cartilage model. Chondrocytes stop dividing when ECM is formed and become
hypertrophic deep in the center of the cartilage model. Hypertrophic chondrocytes stop secreting
collagen and begin to secrete an enzyme essential for mineral deposition called alkaline
phosphatase that then cause the ECM to calcify. Calcification causes remaining chondrocytes to
die because nutrients are difficult to transfer through a calcified matrix. Third, invasion of
cartilage ECM model by expanding blood vessels and terminally differentiated hypertrophic
chondrocytes die by apoptosis or undergo osteogenic transdifferentiation [2]. Osteoblasts begin
to secrete bone matrix around any remaining calcified cartilage and begin form the primary
ossification center. Fourth, primary ossification center spreads as osteoclasts break down newly
formed bone. This causes formation of the medullary cavity in the diaphysis; walls of the
diaphysis will eventually be replaced by compact bone. Last, secondary ossification centers form
in the epiphyses following invasion by branches of the epiphyseal artery.
Fracture repair initially begins with the formation of fracture hematoma at 6-8 hours post
injury. Within the fracture line, blood vessels are broken causing blood to leak out and form a
significant clot around the fracture site. Due to lack of blood circulation near fracture site, nearby
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bone cells die, and inflammation occurs at the affected area. Fibrocartilage callus formation takes
about 3 weeks to occur. Fibroblasts from the periosteum migrate to the fracture site and produce
collagen fibers. Some cells differentiate into chondroblasts to produce fibrocartilage.
Fibrocartilage callus is composed of collagen fibers and cartilage that bridges the gap in injured
tissue. At approximately 3-4 months, bony callus forms in areas close to healthy tissue.
Osteogenic cells differentiate into osteoblasts which begin to lay down spongy bone. Later,
spongy bone tissue replaces fibrocartilage callus. Lastly, osteoclasts resorb dead pieces of broken
bone and spongy bone is replaced by compact bone along the periphery of the fracture (bone
remodeling).
Chondrocyte Maturation
Chondrogenic differentiation of bone marrow-derived stromal cells (BMSCs) is a
complex interactive network between transcriptional factors, extracellular growth factors, and
signal transduction pathways [47,48] (Figure 4). Several comparative studies have shown that the
quality of cartilage produced by using BMSCs is substantially lower than that obtained by using
chondrocytes [46]. Chondrocytes are cartilage-producing cells, which are derived from
mesenchymal stem cells. The early steps of chondrogenesis, including mesenchymal
condensation and the expression of chondrocyte-specific extracellular proteins, are crucially
dependent upon SRY-related HMG box (Sox) family transcription factors, including Sox9, Sox5
and Sox6 [51] (Figure 3).
By contrast, Runt-related transcription factor-2 (RUNX2) regulates the process of
chondrocyte hypertrophy and Runt-related transcription factor 3 (RUNX3) and Forkhead box
A2/3 (Foxa2/3) [51]. Intrinsic chondrogenic differentiation potential of BMSCs is believed to be
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controlled by transcription factors Sox-9 and RUNX-2, whereas TGF, like TGF-β3, as well as
BMPs are some of the most potent inducers of BMSC chondrogenesis [46] (Figure 4). Early in
their maturation chondrocytes express collagen Type II alpha 1 chain (COL2A1). During further
Figure 3: Different combinations of transcription factors drive tissue-specific gene expression in immature versus
hypertrophic chondrocytes. Source Kozhemyakin et al. (2015)

maturation, chondrocytes express crucial gene marker such as collagen Type X alpha 1 chain
(COL10A1). The stromal cell-derived factor-1 (SDF1)/chemokine receptor (CXCR) pathway is a
key regulator for BMSC migration, and, in the absence of SDF1 signal, migration of these cells
to the bone tissue has been found to be impaired [49, 50]. The process of chondrogenic
differentiation includes six phases: mesenchymal cells (chondroprogenitors), condensed
mesenchymal cells, chondrocytes, proliferating chondrocytes, pre-hypertrophic chondrocytes,
and hypertrophic chondrocytes [3]. Endochondral ossification, therefore, requires
chondrogenesis and cartilage hypertrophy as necessary precursors before ossification can
proceed.
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Figure 4: Possible mechanisms operative in cartilage regeneration by mesenchymal stem cells. Source Gupta et al. (2012)

Activation of Insulin Pathway
Activation of the insulin pathway is considered a primary factor involved in the initiation of
chondrogenesis and its progression during bone healing [9]. Insulin is a polypeptide hormone
that directly and indirectly modulates bone metabolism and skeletal regeneration among other
physiological events. The insulin receptor (IR) belongs to a family of receptor tyrosine kinase
(RTK) transmembrane signaling proteins, which include insulin-like growth factor-1 (IGF-1),
and epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) receptors [56].
The IR is initially synthesized as a proreceptor and cleaved to form a 350-400kDa
heterotetrameric receptor composed of two α-subunits and two β-subunits joined by disulphide
bones in a β-α-α-β configuration as illustrated in Fig. 5 [57]. During receptor activation, insulin
binds to one of two binding sites on each of the αβ monomers called, site 1 and site 2 [58]. When
insulin first binds to site 1, a high-affinity cross-linking reaction takes place, allowing site 2 to
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become accessible for ligand binding to activate the receptor [59, 60]. Once bound, the α-subunit
which normally prevents autophosphorylation of the β-subunit, is inhibited causing the kinase
Figure 5: Insulin receptor and the major signal transduction pathways used in tissue repair, biomacromolecules
synthesis and glucose uptake. Source Hrynyk et al. (2014)

activity of the β-subunit to transphosphorylate, changes conformation and increases its own
kinase activity [61]. The signaling cascade begins with the phosphorylation of intracellular
tyrosines located on the β-subunits of the receptor. The phosphorylated tyrosines act as docking
sites, permitting the Shc-transforming protein (Shc) found in the cytosol to bind via their Srchomology-2 (SH2) domains [62-64]. The signal is then transduced via a series of messenger
molecules including Grb2 (growth factor receptor-bound protein-2), which recruits SOS (son of
sevenless), to activate Ras [65]. After activation, Ras (member of the GTP-binding protein
family) carries the signal via mitogen-activated protein kinase kinase kinase (Raf or MAP3K),
mitogen-activated protein kinase (MEK) and extracellular signal-related (ERK) protein kinases.
ERK then translocates into the nucleus where cell transcription is achieved, cell cycle activation
occurs and DNA replicate [62]. The IR signaling pathway leads to tissue repair and wound
healing.
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Several studies have indicated that local insulin treatment may potentially enhance
osseous or fracture healing in non-diabetic animals [52]. In non-diabetic mice, injection of
insulin over the calvarium increased osteoid area, osteoblast surface area, and osteoblast number
[54]. Dedania et al. found that local insulin delivery significantly increased the percent of
mineralized tissue within the endosteal region of the healing defect at 4 and 6 weeks postosteotomy, compared with saline control animals [55]. Functional insulin receptors on rat
osteoblasts have been identified that, when activated, stimulate osteoblast proliferation, and
increase collagen production in vitro [53]. Insulin has been postulated to elicit an anabolic role in
bone via insulin receptor (INSR); however, recent data has shown that the anabolic effect on
bone is acting through an alternative receptor. Increasing data suggests that the IGF-1 receptor
shares similar downstream events with INSR [6]. In vitro studies demonstrate that insulin can
stimulate chondrocyte proliferation, maturation, and activity in collaboration with the local
production of IGF-1 in the pancreas. Insulin exerts direct anabolic effects and promotes
chondrocyte maturation in vitro. [7, 11]. Insulin administration in vivo normalizes glycemic
control and reduces advanced glycation end products (AGE) production, thus it may also
enhance chondrocyte survival indirectly [12, 13]. Insulin treatment on fracture healing in diabetic
patients both in vitro and in vivo have shown to promote chondrocyte maturation leading to
endochondral ossification [7, 11-13, 55]. Poor bone regeneration is thought to result from a
decrease in insulin receptor activation which is needed to transmit signals to initiate tissue
growth and repair, biomacromolecule synthesis, and glucose uptake in tissues.
Zn2+ is the second most common trace metal found in the body, after iron, and is the
fourth most used metal in the world, after iron, aluminum, and copper [66]. Zn2+ has been used
since the time of the ancient Egyptians, in the form of zinc oxide (ZnO), to aide in the healing of
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wounds and burns [67]. Zinc chloride (ZnCl2) have been shown to improve bone healing
outcomes and accelerate bone healing in both non-diabetic and diabetic animal models [9].
Cellular Zn2+ levels are tightly regulated, and disturbances of Zn homeostasis have been
associated with diabetes mellitus. Zn2+ dyshomeostasis, both systemically and in the pancreas,
plays an intricate role in the pathology of both type 1 and type 2 DM [29]. Insulin mimetics have
an insulin-like action both in vitro and in vivo experiments, but they do not build fat like insulin.
It is important to discuss this pathway in detail and to highlight the effect of Zn2+ on these
signaling events in in vitro and in vivo systems [29]. In 1980, the first report of the effectiveness
of a zinc compound to stimulate rat adipocyte lipogenesis, mimicking action of insulin [22].
ZnCl2 was observed to have anti-diabetic effects in streptozotocin-induced type 1 diabetic rats
(STZ-rats) when ZnCl2 was administered orally following the rat adipocyte experiment
previously mentioned. [23, 24, 25].
Insulin-like Effects of ZnCl2
Zinc compounds are used every day in various forms like an astringent, antifungal,
antiseptic, skin protectant, and desensitizer for dentin. Zinc is an intracellular signaling molecule
that plays important roles in growth and development, sensory function, blood clotting,
reproduction, and immune system [27, 28]. Zn2+ enhances tyrosine phosphorylation of multiple
receptor protein tyrosine kinases (R-PTKs), such as insulin receptor (IR), insulin-like growth
factor type-1 receptor (IGF-1R), and epidermal growth factor (EGFR). One of the mechanisms
by which thisis achieved involve an increased production of reactive oxygen species (ROS),
leading to the inhibition of protein tyrosine phosphatase (PTPase) resulting in an increased
tyrosine phosphorylation of R-PTK. Activated R-PTKs phosphorylate multiple downstream
targets such as insulin receptor substrates (IRSs), leading to the phosphorylation and activation

18
of the MAPK/ERK1/2 and the phosphoinositide 3-kinase (PI3-K)/protein kinase B (PKB)/Akt
(protein kinase B) signaling pathways. ERK1/2 pathways through the activation of
Figure 6: The potential mechanism for the insulin-like effects of Zn2+. Source Vardatsikos et al. (2013).

transcription factors contribute to the increased nuclear activity, including gene transcription, cell
growth, and proliferation. PI3-K/PKB/AKT pathway, through its downstream targets, such as
Forkhead box protein O1 (FOXO1), glycogen synthase kinase 3-beta (GSK3-β) and mammalian
target of rapamycin (mTOR) signals an increase in glucose uptake, glucose transport, glycogen
synthesis, lipogenesis and inhibition of lipolysis and gluconeogenesis [9]. It also has potent
antioxidant and anti-inflammatory properties [27] and has been shown to exert anti-diabetic
effects in various experimental models and in a limited number of human studies [29].
Unfortunately, very little is known about the effects of zinc chloride on acceleration of fracture
healing in diabetics. Previous studies of zinc chloride as an insulin mimetic do not provide a
concise understanding on the mechanisms which zinc chloride uses to accelerate fracture healing
in diabetics [22].
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Methodology
Cell Culture
ATDC5 chondrogenic cell line was cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 5% fetal bovine serum (FBS), and 1% L-glutamine, selenium,
penicillin/streptomycin, and transferrin. ATDC5 cells were plated from a frozen stock stored in a
-80⁰C freezer. The frozen stock vile was warmed to room temperature, and then cells were
suspended in growth media and centrifuged for five minutes at 3000rpm. The supernatant was
decanted, and the cells were suspended in fresh growth media and plated as needed. Cells were
checked using an electron microscope to determine confluence, the possibility of contamination,
and cell death. When cells reached 100% confluence, experimental treatments were conducted as
described below.
ZnCl2 Treatment
ATDC5 cells were treated with increasing doses of zinc chloride (ZnCl2) (0μM, 100μM,
1000μM) in triplicate over specific timepoints (2, 4, 24, and 48 hours). ZnCl2-treated ATDC5
cells were harvested in Mammalian Protein Extraction Buffer (mPer) at designated timepoints (2,
4, 24, and 48 hours) for protein expression and RiboZol™ RNA Extraction Buffer for RNA
expression.
Protein Isolation
Adherent ZnCl2-treated ATDC5 cells were harvested with Mammalian Protein Extraction
Buffer at specific timepoints while on ice. Growth media containing ZnCl2 treatment was
aspirated from the plates, rinsed with cold 1X HBSS, and then aspirated again to remove fluid.
Mammalian Protein Extraction Buffer was added to each well and the plate was placed onto a
shaker for ten minutes to coat cells evenly while on ice. Next, a cell scraper was used remove
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adherent cells off the plate, assist in cell lysis, and extract proteins for western blot analysis. The
lysates for each well were stored in the -20⁰C until needed for further analysis.
Western Blotting
Triplicate sets of frozen protein samples in mPer buffer were thawed on ice until
completely defrosted to prevent protein degradation. In separate microtubes, protein sample and
2X SDS with 2-Mercaptoethanol (2-Me) were combined in a 1:1 ratio and centrifuged at 4⁰C.
The protein mixture was heated in a dry bath at 70⁰C for ten minutes to denature the proteins. A
4-12% NuPAGE Bis-Tris gel was run using NuPAGE MOPS Running Buffer solution. The gel
was run for 50 minutes at 200V. Transfer apparatus and four pieces of filters paper were soaked
in transfer buffer solution with methanol; polyvinylidene fluoride (PVDF) membrane was soaked
for one minute in methanol only and rinsed in the NuPAGE transfer buffer solution. The transfer
chamber was set up and sample transfer was for one hour at 30V and 100W. Following transfer,
PVDF membranes were placed in SuperBlock solution (ThermoScientfic, Rockford, IL) for one
hour and rocked at room temperature.
PVDF membranes were rinsed 3X in 1X Transfer Buffer Saline with 0.1% Tween (TBST) for five minutes then placed in primary antibody solution, stored +4⁰C refrigerator, and slowly
shaken overnight. The primary antibody solution consisted of 10μM GAPDH, 10μM Akt (pan)
or phospho-Akt (pan), 0.1% SuperBlock, and 1X TBS-T. After overnight incubation, PVDF
membranes were rinsed 3X in 1X TBS-T for five minutes then placed in secondary antibody for
one hour and shaken at room temperature. The secondary antibody solution consisted of 0.2μM
anti-goat IgG-conjugated antibody, 0.2μM anti-mouse IgG-conjugated antibody, TBS-T, and
0.1% SuperBlock. The membranes were rinsed twice in 1X TBS-T and once in 1X TBS to
remove any remaining secondary antibody then placed in Pierce® Enhanced Chemiluminescence
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(ECL) Western Blotting Substrate to view under UV light using the FluorChem E System
(ProteinSimple, San Jose, CA).
RNA Isolation
To prepare for RNA isolation of confluent adherent cells, all equipment was sterilized
with 70% ethanol and confined to a specific location within the laboratory to minimize
contamination and RNA degradation by RNases. ATDC5 cells were treated with ZnCl2 at 0μ,
100μM, 1000μM dosages and seeded (triplicate) in 6-well plates with similar method used for
protein isolation. Post-treatment, media was aspirated and RiboZol™ RNA Extraction Reagent
was used to isolate RNA. ATDC5 cells were lysed by passing them through the tip of the pipette
several times to disrupt the cell wall and release RNA. Next, lysed ATDC5 cells were transferred
into an RNase-free microtubes and incubated at room temperature for five to ten minutes.
RiboZol™ solution was mixed with 100μL of chloroform in a tightly secured microtubes and
shaken vigorously for fifteen seconds to thoroughly mix the samples; this solution was incubated
at room temperature for three minutes to allow phases to begin to separate. The samples were
centrifuged at 12,000rpm for fifteen minutes at +4⁰C to separate the mixture into three phases:
clear aqueous phase (RNA), white interphase (DNA), and pink phenol-chloroform phase
(protein).
Up to 80% of the clear aqueous phase exclusively containing RNA was carefully
removed by pipette, placed in a fresh RNase-free microtube, and a volume of isopropanol was
added to initialize homogenization. The samples were incubated for ten minutes at room
temperature then centrifuged at 12,000rpm for ten minutes at +4⁰C. Supernatant was removed
without disrupting the precipitate RNA pellet that was located at the bottom of the RNase-free
microcentrifuge tube. The pellet was washed once with a volume of 75% ethanol that was
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prepared with DEPC-treated RNase-free water, vortexed and centrifuged at 7,500rpm for five
minutes at +4⁰C. The ethanol wash was carefully removed without dislodging the RNA pellet.
The pellet was briefly air-dried for five to ten minutes at room temperature until most of the
remaining alcohol evaporated from the microcentrifuge tube. The RNA pellet was re-dissolved
into RNase-free water and passed through a pipette tip several times until completely dissolved.
RNA yield and purity were determined by absorbance at A260 with a BioDrop DUO (UK,
England) immediately after isolation process. RNA purity was determined by the ratio of
absorbance (A260/280). Purity and concentration of RNA were confirmed via gel electrophoresis
described below.
RNA Gel
RNA samples were prepped for a 1% agarose gel to verify that RNA was intact after
isolation process. 1% agarose gel was made with 1X 3-(N-Morpholino)propanesulfonic Acid
(MOPS) buffer. Approximately 20-25mL of agarose solution was poured into the gel
electrophoresis apparatus then allowed to solidify for 20-40 minutes. 1X MOPS buffer was
poured over the gel until submerged and acted as running buffer during the process. The samples
were prepped in separate RNase-free microcentrifuge tubes and included 1μg of RNA sample,
1X Sucrose Gel Loading Dye, and RNase-free water. All prepped samples were vortexed,
centrifuged, and loaded into the agarose gel. The gel apparatus was set at 90V and ran for one
hour; the RNA gel was placed on a rocker at room temperature for fifteen minutes in RNase-free
water with GreenGlo™ Safe DNA Dye. The results of the RNA gel were visualized under UV
light and RNA samples were viewed; RNA samples that were confirmed to be intact were used
for reverse transcription (RT). The original RNA samples were stored at -80⁰C to prevent
degradation.
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Reverse Transcription (RT)/Polymerase Chain Reaction (PCR)
RNA samples were removed from -80⁰C storage and thawed on ice; two master mixes
were prepared for reverse transcription (RT) and placed on ice until aliquoted into RNA samples.
One microgram of each RNA sample was combined with 5mM dNTPs and 5mM oligo dTs and
brought up to final volume of 16μL with RNAse free water. The RNA samples were vortexed
and centrifuged for thirty seconds at 12,000rpm. The samples were inserted into a dry bath set at
65⁰C for three minutes for denaturation then immediately returned to ice to reduce degradation.
These cooled RNA samples were combined with 2μL of 10X Standard RT (Taq) Buffer, 1μL of
RNAOUT, and 1μL of reverse transcriptase enzyme. Combined RNA reactions were vortexed,
and centrifuged again for thirty seconds at 12,000rpm. RNA reactions were incubated in a water
bath set at 42⁰C for one hour. After incubation, microcentrifuge tubes were placed in a dry bath
at 95⁰C for ten minutes. Post-denaturation, RT samples were cooled at room temperature to
promote annealing. RT samples were prepared for polymerase chain reaction (PCR) to confirm
the presence of complimentary DNA (cDNA).
Each PCR reaction contained 2.5μL of cDNA, 2.5μL 10X Standard RT (Taq) Buffer,
2.5μL 5mM dNTPs, 1.5μL 10mM primer mix, and 0.125μL Taq polymerase. The samples were
vortexed then placed in the PCR machine and the reaction proceeded for two hours and fifteen
minutes. DNA gel was performed to confirm RT/PCR process was successful. Table 1 is the
thermocycling conditions used for routine PCR:
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Table 1: Thermocycling conditions for a routine PCR.

STEP

TEMP (⁰C)

TIME

Initial Denaturation

95⁰C

30 seconds

95⁰C

15-30 seconds

45-68⁰C

15-60 seconds

68⁰C

1 minute/kb

Final Extension

68⁰C

5 minutes

Hold

4-10⁰C

40 Cycles

DNA Gel Electrophoresis
DNA gel electrophoresis was setup similarly as a RNA gel, except 1X TBE Buffer is
used instead of 1X MOPS Buffer with a 2% agarose gel. cDNA samples were combined with 1X
Sucrose Loading Dye and ran for one hour at 90V. The DNA gel was submerged in dH2O with
GreenGlo™ Safe DNA Dye and rocked for fifteen minutes. DNA gel was viewed under UV
light to determine if RNA was successfully converted into cDNA during PCR process.
Quantitative PCR (qPCR)/Gene Expression
Prior to qPCR, cDNA samples were diluted 1:10 to increase number of reactions that
could be performed using a 96-well qPCR plate; 2.5μL of cDNA was added prior to distribution
of the master mix into each well. The following solutions were thawed on ice and combined into
a sterile microcentrifuge tube for each reaction: 12μL of 2X Absolute Blue SYBR, 1.75μL each
of 1μM forward and reverse primer per sample, 6.5μL per sample RNase-free dH2O. The primers
used for qPCR and gene expression were glyceraldehyde-3-phosphate dehydrogenase (GAPDH
– housekeeping gene) for normalization, collagen type II alpha 1 chain (COL2A1), collagen type
X alpha1 chain (COL10A1), Runx2, mTOR, ALP, and β-actin (Table 4). Total volume of the
master mix solution was 22.5μL per well. The total volume of each well for this procedure was
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25μL (22.5μL of master mix plus 2.5μL of cDNA). Tables 2 and 3 are the qPCR thermal cycling
program and melt curve program:
Table 2: qPCR Thermal Cycling Program

Temperature (⁰C)

Time

Number of cycles

Enzyme Activation

95⁰C

15 min.

1

Denaturation

95⁰C

15 sec.

40

Annealing

50-60⁰C

30 sec.

40

Extension

72⁰C

30 sec.

40

Table 3: Melt Curve Program

Temperature (⁰C)

Time

Number of cycles

Denaturation

95⁰C

30 sec.

1

Starting Temp.

60⁰C

30 sec.

1

Melting Temp.

60⁰C

10 sec.

80

Table 4: Primer sequences for detection of COL2A1, COL10A1, β-actin, RUNX2, and mTOR were based on the coding
sequences of the respective mRNAs.

Oligo Name
gapdh_F
gapdh_R
COL2A1_F
COL2A1_R
COL10A1_F
COL10A1_R
mTOR_F
mTOR_R
RUNX2_F
RUNX2_R
ALP_F
ALP_R
B-actin_F
B-actin_R

Sequence (5’ to 3’)
ACCACAGTCCATGCCATCAC
TCCACCACCCTGTTGCTGTA
TGGGTGTTCTATTTATTTATTGTCTTCCT
GCGTTGGACTCACACCAGTTAGT
CATGCCTGATGGCTTCATAAA
GCGTTGGACTCACACCAGTTAGT
CCATCCAATCTGATGCTGGA
GGTGTGGCATGTGGTTCTGT
GACGAGGCAAGAGTTTCACC
GGACCGTCCACTGTCACTTT
CCGATGGCACACCTGCTT
GGAGGCATACGCCATCACAT
GACAGGATGCAGAAGGAGATTACTG
CCACCGATCCACACAGAGTACTT
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The CT values for each gene (Table 4) were normalized with GAPDH CT values. Gene
expression was calculated using the 2-ΔΔCt method.
Alizarin Red Staining
Briefly, calcium containing cells were determined by Alizarin Red Staining (ARS).
ATDC5 cells were treated under four different conditions in 12-well plates and harvested at
timepoints: 2, 4, 7, 10, 14, 17, 21, and 28 days. The cells were treated in triplicate with 1ug/ml of
insulin, 10μM of ZnCl2, 100μM of ZnCl2 and 100μM of vanadium. The 12-well plates were
washed with HBSS then fixed with 10% (v/v) formaldehyde at room temperature for 15 minutes.
Next, plates were washed twice with HBSS and 40mM Alizarin Red Staining (ARS) solution
was pipetted into each well. The ARS stained plates were placed very carefully on a rocker at
room temperature for 20 minutes. ARS solution was aspirated from ATDC5 cell plates then
washed four times with HBSS while shaking for five minutes. To facilitate the removal of any
remaining liquid, the plate was angled for two minutes and re-aspirated. For quantification of
staining, 10% (v/v) acetic acid was added to each well and incubated at room temperature for 30
minutes on a rocker. Using a cell scraper, the monolayer was scraped from the plate and
transferred with 10% (v/v) acetic acid to a clean centrifuge tube. The samples were vortexed
briefly for 30 seconds then warmed for 10 minutes in a dry bath at 85⁰C. Afterwards, the samples
were placed on ice for five minutes then centrifuged at 13,000rpm for 15 minutes. 500μL of
supernatant was transferred into a new centrifuge tube and 200μL of 10% (v/v) ammonium
hydroxide was added to the supernatant. Supernatant was analyzed in aliquots of 150μL in
triplicate in a 96-well plate and read at 405nm.

27
Glacial Blue Staining
ATDC5 cell proteoglycans were treated under four different conditions in 12-well plates
and harvested at timepoints: 2, 4, 7, 10, 14, 17, 21, and 28 days. The cells were treated in
triplicate with 1ug/ml of insulin, 10μM of ZnCl2, 100μM of ZnCl2 and 100μM of vanadium. The
12-well plates were washed twice with HBSS then fixed with 100% cold methanol for five
minutes. Next, plates were stained with 0.1% Alcian Blue in 0.1M HCl and rocked overnight.
The ATDC5 cell monolayers were washed three times with HBSS. Proteoglycans were extracted
with 6M guanidine-HCl overnight. Proteoglycan concentration was read at 595nm.
Results
Treatment with Zinc Chloride Activates Phospho-Akt and Akt Protein Expression
Zinc chloride (ZnCl2) has been shown in several studies to induce chondrogenesis and
promote chondrocyte maturation [22, 35-38]. To elucidate possible mechanisms by which ZnCl2
induced chondrogenesis, phospho-Akt and Akt expression levels were measured at 2, 4, 24, and
48 hours post-treatment in the ATDC5 chondrogenic cell line. Figure 8 shows that ZnCl2
treatment upregulated phospho-Akt/Akt expression greater than the control, 0μM ZnCl2 group.
The 1000μM ZnCl2 dose showed significantly more phospho-Akt expression compared to both
0μM ZnCl2 and 100μM ZnCl2 dosage groups at 2, 4, and 24 hours. The 1000μM ZnCl2 dose
increased phospho-Akt expression by 19-fold, at 4 and 24 hours post-treatment (P<0.025).
Phospho-Akt/Akt expression treated with 0μM ZnCl2 did not activate phospho-Akt/Akt
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expression. ATDC5 cells show a 4, 5, 15-fold increase when treated with 1000μM ZnCl2 at 2, 4,
and 24 hours post-treatment represented by Figure 7.
Figure 7: Phospho-Akt Protein Expression of Zinc Chloride (ZnCl2) Treated ATDC5 Cells.

Figure 8: Phospho-Akt and Akt protein expression in ZnCl2 treated ATDC5 cells. Cells were treated with denoted
concentrations of ZnCl2. A) 4 hours; B) 48 hours.

Figure 8 is an immunoblot of phospho-Akt and Akt expression at 4 and 48 hours posttreatment. At 4 hours post-treatment, both phospho-Akt and Akt are expressed in all ZnCl2
doses. The 1000μM ZnCl2 dose had significant phospho-Akt antibody expression at 4 hours
compared to the 0μM and 100μM ZnCl2 doses. At 48 hours post-treatment there was little to no
phospho-Akt expression in any treatment group, but Akt protein was expressed in all ZnCl2
doses.
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Treatment with Zinc Chloride Results in Upregulation of Chondrocyte Gene Expression Markers
Collagen markers were shown to have specific binding with cDNA generated from PCR.
Figure 9 shows that ZnCl2 treated ATDC5 cells expressed specific gene markers at 2, 4, 24, and
48 hours post-treatment when normalized with housekeeping gene, GAPDH. Collagen type II
alpha chain is expressed in early chondrocyte maturation while collagen type X alpha chain is
expressed by hypertrophic chondrocytes prior to apoptosis.
Figure 9: Gene expression of ZnCl2 treated ATDC5 cells over time.

The 100μM ZnCl2 dose caused a 2.9- (P=0.011), 6.1- (P<0.001), and a 1,6-fold (P<0.001)
increase in col2a1 mRNA levels at 2, 24, and 48 hours (Figure 9A). The 1,000μM ZnCl2 dose
also increased col2a1 mRNA levels by 3.9- (P=0.003), and 7.6-fold (P<0.001) at hours 24 and
48 hours. At 48 hours, the 100μM ZnCl2 treated ATDC5 cultures had 0.25-fold less (P=0.009)
collagen type X alpha chain 1 (col10a1) mRNA as compared to 0μM ZnCl2 (Figure 9B). The
1,000μM dose of ZnCl2 significantly reduced col10a1 expression as compared to controls at 4
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(P=0.018) and 48 (P<0.001) hours after treatment. These data suggest that the 100μM dose of
ZnCl2 stimulates chondrocyte differentiation and that the 1,000μM dose may inhibit this process.
Other gene markers were quantified to determine the role of ZnCl2 in the promotion of
chondrogenesis. There were no significant differences found in Runx2 expression when
compared between treatment groups over time (Figure 9C). The 100μM ZnCl2 dose reduced
mTOR gene expression at 24 hours (P=0.011) as compared to the control groups but no other
significant differences were detected. The 1000μM ZnCl2 dose significantly reduce mTOR
expression at 48 hours (P=0.005) as compared to the control group (Figure 9D).
Treatment with Zinc Chloride Upregulates Proteoglycan Synthesis
Figure 10: Quantification of Proteoglycans after ZnCl2 treatment over time.

Proteoglycan synthesis was measured with Alcian Blue staining on insulin-treated and
100μM and 1000μM ZnCl2 dose treated ATDC5 cell cultures. ZnCl2 treatment was shown to
promote proteoglycan synthesis in ATDC5 cells and statistical differences were found after twoway ANOVA analysis (Table 5). The data showed that proteoglycan synthesis was highest
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between days 4 and 14 in both control and 100μM ZnCl2 treated ATDC5 cells (Figure 10, Table
5). On day 4, controls had produced significantly more proteoglycans than either ZnCl2 treatment
group. After two weeks (day 14), 100μM ZnCl2 treated cells had 1.5-fold more proteoglycans
when compared to insulin-dependent media (IDM) controls. Also, the data analysis shows the
1000μM ZnCl2 dose had a significant decrease in proteoglycan concentration between days 4 and
14 and demonstrated high levels of cell death after treatment.
Table 5: Two-Way Analysis of Variance: Effect on Treatment on Proteoglycan with time points.

Comparison of Treatment Groups at Each Time Point
(Holm-Sidak Test P Values)
100uM ZnCl2 vs
Control

1000uM ZnCl2 vs
Control

2

0.989

0.983

100uM ZnCl2
vs 1000uM
ZnCl2
0.904

4

0.001

<0.001

<0.001

7

0.838

<0.001

<0.001

10

<0.001

<0.001

<0.001

14

0.532

<0.001

<0.001

21

0.204

0.402

0.062

Treatment with Zinc Chloride Promotes Calcium Deposition
In comparison to proteoglycan synthesis, calcium deposition was measured during
chondrocyte differentiation with Alizarin Red staining (ARS) on ZnCl2 treated ATDC5 cells.
ATDC5 cells were treated every two days under three conditions: IDM (control), 10μM and
100μM ZnCl2, and VCl2 after reaching confluence. Cells were harvested on days 2, 4, 7, 10, 14,
17, 21, 24, and 28 days post-treatment. Based on statistical data analyzed with two-way analysis
of variance test using time and treatment as factors, calcium deposition was shown to be similar
for 100μM ZnCl2 dose and IDM control samples between days 2-17 (Figure 11 and 12). At days
21, 24, and 28, the 100μM ZnCl2 dose increased calcium deposition when compared to IDM
controls. However, there were no significant differences in calcium deposition between ATDC5
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cells treated with 10μM ZnCl2 and IDM controls at any time point (data not shown). After day 7,
the 1000μM ZnCl2 dose caused significant cell death in ATDC5 cells and was not evaluated in
ARS assay.
Figure 11: Quantification of Calcium Deposition of ZnCl2 Treatment.

Figure 12: ARS stain assay on ZnCl2 treated ATDC5 cells. A) 2 days; B) 4 days; C) 7 days; D) 10 days; E) 14 days; F) 17
days; G) 21 days; H) 24 days; I) 28 days Source Burgess (2017)
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Discussion
Zinc is an essential micronutrient required for many cellular processes, especially for the
normal development and function of the immune system [68]. Zinc is an essential trace element
to the function of metabolism [69]. Zinc deficiency results in a retardation of bone growth,
development, and maintenance of bone health [70,71]. Zinc2+ acts to increase bone formation
and mineralization, decrease bone resorption and stimulate alkaline phosphatase (ALP) activity,
in both calvaral organ cultures and osteoblast cell cultures [72-75]. Studies have demonstrated
that zinc has an anabolic stimulatory effect on bone formation and mineralization in vivo and
vitro. For example, Yamaguchi and Takahashi demonstrated that administration of zinc sulfate
for 3 days produced dose dependent increases in the contents of zinc, deoxyribonucleic acid
(DNA), collagen and calcium, and the activity of ALP in the femoral diaphysis (cortical bone) of
weanling rats [76]. Zinc activation of ALP in bone tissues may first cause activation of ALP and
stimulation of collagen synthesis in osteoblasts, which are involved in bone mineralization and
calcification [77].
Fracture healing studies have demonstrated that insulin mimetics like zinc chloride
(ZnCl2) can enhance bone healing and stimulate bone growth via production of TGF-β1 and IGF1 in bone tissues of newborn rats [78]. The mechanism by which insulin mimetic, ZnCl2,
improves bone healing is poorly understood. The current data suggests that this insulin mimetics
promote and enhance chondrogenesis [79], osteoblastogenesis [80], and prevents osteoblast
proliferation [81] by acting similar to insulin. Fukumoto et al. demonstrated in vitro that IGF-1
significantly increased chondrogenesis in dose-dependent manner when administered
continuously throughout the culture period of periosteal explants from the medial proximal tibia
of 2-month old rabbits. IGF-1 and TGF-β1 for the first 2 days, enhanced overall total cartilage
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growth. Immunohistochemistry for proliferating cell nuclear antigen (PCNA) demonstrated that
combining IGF-1 with TGF-β1 gave the strongest proliferative stimulus early during
chondrogenesis [82]. Other data shows that in vivo insulin acts as an anabolic agent in bone
healing and regeneration using Diabetes Mellitus Type I (T1DM) rat models because impaired
insulin signaling in bone-forming cells results in a secondary and local insulin-like growth factor
1 (IGF-1) deficiency [83]. Zinc chloride’s role on chondrocytes has not been thoroughly
evaluated. We hypothesized that zinc chloride could enhance chondrocyte maturation and
differentiation like insulin and stimulate transcriptional expression of chondrogenic markers like
collagen type II alpha 1 chain (COL2A1) and collagen type X alpha 1 chain (COL10A1).
Our data shows that ZnCl2 treatment can induce chondrocyte differentiation in the
absence of insulin as measured by both proteoglycan quantification and calcium deposition. Our
data coincides with Yamaguchi et al. who demonstrated in vitro that zinc could stimulate bone
collagen production and increase bone calcium content in calvaria of weaning rats [73]. Our data
also shows that ZnCl2 induces chondrocyte differentiation by transcriptional upregulation of
chondrogenic markers of COL2A1 and COL10A1. These chondrogenic markers are expressed as
hallmarks of chondrogenesis and endochondral ossification. ZnCl2 treatment in vivo
demonstrated mechanical strength, including increased torque to failure, torsional rigidity, shear
modulus, and shear stress [85]. In this study [85], fracture callus showed an increased percent
cartilage and mineralized tissue at day 7 in ZnCl2 treated group. Cell proliferation was increased
by local ZnCl2 in both subperiosteal and gap callus regions. VEGF and IGF-1 levels within the
fracture callus were increased by local ZnCl2 treatment. This study demonstrates the potential
role of local ZnCl2 as an adjunct for fracture healing [85]. This suggests that ZnCl2 treatment
contributes to growth factor expression, which stimulates cell proliferation, cell differentiation,
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and enhances endochondral ossification. Our data suggests that ZnCl2 upregulation of gene
markers col2a1 and col10a1 are dose-dependent and expressed in during chondrocyte maturation
as measured by gene expression quantification.
Zinc chloride has been demonstrated to possibly function through similar methods as
insulin, but the mechanism by which ZnCl2 induces chondrogenesis is still uncertain.
Chondrogenesis has a multitude of signaling regulators and mechanisms regulate chondrocyte
maturation and cartilage production. These include various signaling pathways, including
fibroblast growth factor (FGF), transforming growth factor β (TGF-β)/bone morphogenetic
proteins (BMPs), Wnt/β-cats in, Hedgehog, Notch, hypoxia, and angiogenic signaling pathways
[86]. Our data demonstrated that ZnCl2 does not induce PI3K-Akt pathway to stimulate Runx2
transcriptional expression within the first 48 hours of treatment. Runx2 expression was compared
between ZnCl2 treatment groups over time, no significant differences were found. Runx2 and
Runx3 are essential for chondrocyte maturation and regulation of limb growth, and these effects
are carried out through RunX-induced expression of Indian hedgehog (Ihh). Ihh promotes
chondrocyte differentiation via expansion of Sox9 expression [86]. Our data shows that ZnCl2
treatment had no effect on Runx2 expression. This suggests Runx2 is expressed through another
pathway. Future experiments could extrapolate other pathways in which ZnCl2 induce
chondrogenesis. In addition, our gene expression show that ZnCl2 reduces transcriptions
expression of mammalian Target of Rapamycin (mTOR), which is an inhibitor of Insulin
Receptor Substrate-1 (IRS-1) [87]. The serine/threonine kinase, mTOR, is a protein kinase of the
PI3K/Akt signaling pathway [89]. Phornphutkul et al. demonstrated that in the presence of
rapamycin, mTOR was still expressed in late gestation fetal rats [87]. Rapamycin had a
significant effect on early hypertrophic chondrocytes and minimal effect on chondrocyte
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proliferation. Effect of rapamycin was measured with a phosphorylated-S6 stain [87].
Phosphorylated-S6 is a ribosomal protein and marker for activity of mTOR. This demonstrates
that mTOR inhibitor, rapamycin, does not significantly affect chondrocyte proliferation. Our data
suggests that with reduced mTOR expression, it is possible that IRS-1 can upregulate expression
of various downstream targets of PI3K/Akt signaling pathway. Since mTOR is an Insulin
Receptor Substrate-1 (IRS-1) inhibitor, our data suggests IRS-1 may contribute in ZnCl2 induced
chondrogenesis. Current research suggests that FGF and insulin have a synergistic effect to
induce chondrogenesis and work long-term collaboratively to produce fully functional cartilage
[88]. As previously mentioned, chondrogenesis can be induced by a plethora of signaling
pathways. Therefore, in the future we plan to investigate the mechanism by which ZnCl2 affects
chondrogenesis utilizing next generation sequencing (NGS).
Overall, we demonstrate that zinc chloride (ZnCl2) can induce chondrogenesis and
upregulate expression of downstream targets of both insulin and PI3K/Akt signaling pathway.
We demonstrated that zinc chloride treatment on ATDC5 chondrogenic cell line promotes
chondrocyte differentiation as seen by transcription upregulation of chondrogenic hallmarks,
COL2A1 and COL10A1. 100μM ZnCl2 treatment group was the most abundant of proteoglycan
content and calcium deposition when compared with IDM controls. This demonstrates that ZnCl2
was capable of inducing chondrocyte differentiation in vitro.
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